Vivani Medical (VANI) Projected to Post Earnings on Tuesday

Key Points

• Vivani Medical (NASDAQ: VANI) is set to release its Q2 2025 earnings on August 12th, with analysts predicting a loss of ($0.09) per share.
• In its last quarterly report on May 13th, Vivani posted earnings of ($0.11) EPS, missing analyst estimates by a margin of ($0.01).
• HC Wainwright has recently reaffirmed a "buy" rating on the company's shares, setting a price target of $4.00.

Vivani Medical (NASDAQ:VANI - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

Vivani Medical (NASDAQ:VANI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts expect Vivani Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vivani Medical Price Performance

Shares of VANI stock traded up $0.02 during trading on Friday, reaching $1.38. The company's stock had a trading volume of 7,789 shares, compared to its average volume of 108,733. Vivani Medical has a 1-year low of $0.91 and a 1-year high of $1.80. The stock's 50-day moving average price is $1.33 and its 200 day moving average price is $1.18. The company has a market capitalization of $81.46 million, a price-to-earnings ratio of -3.20 and a beta of 2.99.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and issued a $4.00 price target on shares of Vivani Medical in a research note on Monday, May 19th.

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.